InsiderDB

Lobbying disclosures · Lobbying report

UTHR: third_quarter 2026 lobbying report

Issues related to organs and xenotransplantation.

Follow UTHR
Became public
Oct 20, 2026, 1:31 AM EDT
Event / period date
Not stated
Collected
Nov 11, 2026, 11:48 AM EST

Why this is connected

Legal-name match: UNITED THERAPEUTICS CORPORATION is UNITED THERAPEUTICS Corp (https://www.sec.gov/Archives/edgar/data/1082554/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).

Reported lobbying amounts

Income: $80,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/04729ca7-a61c-4662-bdb0-674f5241d93a/","filing_uuid":"04729ca7-a61c-4662-bdb0-674f5241d93a","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/04729ca7-a61c-4662-bdb0-674f5241d93a/print/","filing_document_content_type":"text/html","income":"80000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jonathon Jones, Partner","dt_posted":"2026-10-20T01:31:42-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"750 9th Street NW","registrant_address_2":"Suite 501","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":20744,"url":"https://lda.gov/api/v1/registrants/20744/","house_registrant_id":31587,"name":"TIBER CREEK GROUP","description":"Government Relations.","address_1":"750 9th Street NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"GRACE BAUM","contact_telephone":"+1 202-381-6896","dt_updated":"2026-07-20T13:07:00.819992-04:00"},"client":{"id":69289,"url":"https://lda.gov/api/v1/clients/69289/","client_id":69289,"name":"UNITED THERAPEUTICS CORPORATION","general_description":"Biotechnology and pharmaceutical manufacturing.","client_government_entity":null,"client_self_select":false,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-09-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to organs and xenotransplantation.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":53494,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"MCKECHNIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143334,"prefix":"mr","prefix_display":"MR.","first_name":"DANIEL","nickname":null,"middle_name":"HOWARD","last_name":"ZAWITOSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107185,"prefix":null,"prefix_display":null,"first_name":"COREY","nickname":null,"middle_name":null,"last_name":"MALMGREN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107259,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"KIRKLAND","last_name":"TWOMEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Congressional trading in UTHR

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.